• Our scientific experts take care of your drug development - Biotrial

Key Scientific Experts

Our Executive Leadership and our Scientific Experts are committed to delivering innovative solutions and to assisting your company using our extensive experience in pharmaceutical research and clinical development.


Jean-Marc Gandon, President & CEO, completed his studies in the United States in the late 1980’s and he returned to France with the aim of creating Biotrial, a scientifically driven service provider to the pharma biotech industry. In addition to Dr. Gandon's role as Biotrial’s President, he is also actively involved in regional development; he is the President of ID2Santé, as well as a member of the board of Directors of Rennes University I, Rennes School of Pharmacy and Rennes Chamber of Commerce.


Alain Patat is Chief Medical & Scientific Officer and Head of Regulatory Affairs. Dr. Patat has held several senior management positions within the industry, as International Project Leader in early development and Head of Exploratory Medicine with Roussel Hoechst and  Synthelabo Research, and Head Early Development & Translational medicine Europe for Wyeth, before joining Biotrial in 2005. He is member of ASCPT, ACCP, BPS, SFPT amongst other scientific societies. He is a member of the board of the Club Phase I as well as a regular reviewer of the journal of the American College of Clinical Pharmacology.


Christophe Drieu La Rochelle is the Head of Biotrial's Non-Clinical Pharmacology Department. He obtained his Ph.D. under Prof. JF Giudicelli at the University of Paris South in 1991, and has gone on to author over 35 peer-reviewed publications. Dr. Drieu La Rochelle worked for a number of pharmaceutical companies (Roussel Uclaf, UPSA and Synthélabo Recherche), across disease areas such as heart failure, angina pectoris, venous insufficiency and acute kidney injury. He is now an adjunct Professor of Safety Pharmacology at the University of Rennes as well as being an active member of the Safety Pharmacology Society, American Heart Association and the British Pharmacological Society.


Philippe Danjou, is an MD with training in Clinical Pharmacology and Pain Management, and has over 30 years of academic and industry experience in clinical research. He has joined Biotrial in 2012 as Senior Director R & D with extensive knowledge in pain and neuropsychopharmacology acquired in France (Pitié Salpétrière) and at the New York Psychiatric Institute. Prior to this, he held positions as Head of Clinical Pharmacology in several pharmaceutical groups for 19 years has held several positions as Worldwide Clinical Pharmacologist for Synthélabo, Head of European Early Development Group for Wyeth, Head of Early Development for Sanofi and Head of CNS Early Development for Merck Sharpe & Dohme. Dr. Danjou has a PhD in Clinical and Experimental Pharmacology and is board certified for the advanced treatment of pain.